LOXO TRK 15003

About this trial

This is a multicenter, open label, Phase 1/2 study in pediatric patients with advanced solid or primary CNS tumors. LOXO‑101 (larotrectinib) will be administered orally (PO) twice daily (BID), with the dose adjusted by body surface area.

Patient Profile

Paediatric neoplasm or CNS neoplasm

Where’s this trial being run?

Crumlin Children’s Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: LOXO TRK 15003
Number: 18-36
Full Title:

A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors.

Principal Investigator: Dr Cormac Owens
Type: Industry Sponsored


Recruitment Started: Global: Dec 2015
Ireland: Oct 2018
Global Recruitment Target: 112
Ireland Recruitment Target: Not Available